| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S00432-018-2696-3 |
| P698 | PubMed publication ID | 29959569 |
| P50 | author | Francesco Marampon | Q39185685 |
| Annunziata Mauro | Q59682742 | ||
| Marina Bouché | Q59691899 | ||
| P2093 | author name string | Paolo Berardinelli | |
| Claudio Festuccia | |||
| Giovanni Luca Gravina | |||
| Vincenzo Tombolini | |||
| Daniela Musio | |||
| Francesca De Felice | |||
| Andrea Del Fattore | |||
| Bianca Maria Zani | |||
| Carmela Ciccarelli | |||
| Agnese Di Rocco | |||
| P2860 | cites work | Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A | Q24290420 |
| Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method | Q25938999 | ||
| Broad targeting of angiogenesis for cancer prevention and therapy | Q27002903 | ||
| Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012 | Q29615661 | ||
| A network of immediate early gene products propagates subtle differences in mitogen-activated protein kinase signal amplitude and duration. | Q34551716 | ||
| MEK/ERK inhibitor U0126 increases the radiosensitivity of rhabdomyosarcoma cells in vitro and in vivo by downregulating growth and DNA repair signals | Q34721752 | ||
| Modelling Myc inhibition as a cancer therapy | Q34811008 | ||
| Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis | Q35207795 | ||
| Radiotherapy-induced plasticity of prostate cancer mobilizes stem-like non-adherent, Erk signaling-dependent cells | Q35579329 | ||
| In vitro and in vivo model systems used in prostate cancer research | Q35806390 | ||
| The life cycle of C-myc: from synthesis to degradation | Q35910342 | ||
| Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils | Q36038823 | ||
| Key role of MEK/ERK pathway in sustaining tumorigenicity and in vitro radioresistance of embryonal rhabdomyosarcoma stem-like cell population. | Q36599973 | ||
| Ki-67 is required for maintenance of cancer stem cells but not cell proliferation. | Q36905903 | ||
| The role of hypoxia and acidosis in promoting metastasis and resistance to chemotherapy | Q37663179 | ||
| Therapeutic Approaches Targeting MYC-Driven Prostate Cancer | Q37676253 | ||
| Trametinib: first global approval | Q38121015 | ||
| Myc and cell cycle control. | Q38202390 | ||
| Progress and controversies: Radiation therapy for prostate cancer | Q38252429 | ||
| Tyrosine kinase Etk/BMX is up-regulated in human prostate cancer and its overexpression induces prostate intraepithelial neoplasia in mouse | Q38310622 | ||
| c-Myc Sustains Transformed Phenotype and Promotes Radioresistance of Embryonal Rhabdomyosarcoma Cell Lines. | Q38776254 | ||
| MAP Kinases and Prostate Cancer | Q38791344 | ||
| KI67 and DLX2 predict increased risk of metastasis formation in prostate cancer-a targeted molecular approach | Q38849399 | ||
| Tadalafil modulates aromatase activity and androgen receptor expression in a human osteoblastic cell in vitro model. | Q38857929 | ||
| Hypoxia sustains glioblastoma radioresistance through ERKs/DNA-PKcs/HIF-1α functional interplay. | Q39010806 | ||
| Close correlation between MEK/ERK and Aurora-B signaling pathways in sustaining tumorigenic potential and radioresistance of gynecological cancer cell lines. | Q39067088 | ||
| PXD101 potentiates hormonal therapy and prevents the onset of castration-resistant phenotype modulating androgen receptor, HSP90, and CRM1 in preclinical models of prostate cancer | Q39178894 | ||
| Compensatory upregulation of tyrosine kinase Etk/BMX in response to androgen deprivation promotes castration-resistant growth of prostate cancer cells | Q39689418 | ||
| Down-regulation of c-Myc following MEK/ERK inhibition halts the expression of malignant phenotype in rhabdomyosarcoma and in non muscle-derived human tumors. | Q40245452 | ||
| Myc confers androgen-independent prostate cancer cell growth | Q40271517 | ||
| Negative autoregulation of c-myc transcription | Q41206626 | ||
| Discovery of a selective irreversible BMX inhibitor for prostate cancer. | Q42711869 | ||
| Total ERK1/2 activity regulates cell proliferation | Q46109721 | ||
| Pharmacological targeting of the ephrin receptor kinase signalling by GLPG1790 in vitro and in vivo reverts oncophenotype, induces myogenic differentiation and radiosensitizes embryonal rhabdomyosarcoma cells. | Q47848908 | ||
| Decreased NKX3.1 protein expression in focal prostatic atrophy, prostatic intraepithelial neoplasia, and adenocarcinoma: association with gleason score and chromosome 8p deletion. | Q52575009 | ||
| Immortalization of primary human prostate epithelial cells by c-Myc. | Q53359625 | ||
| Copy number alterations of c-MYC and PTEN are prognostic factors for relapse after prostate cancer radiotherapy | Q57790286 | ||
| Expression of the c-myc protooncogene in human prostatic carcinoma and benign prostatic hyperplasia | Q68952062 | ||
| Detection of chromosomal anomalies and c-myc gene amplification in the cribriform pattern of prostatic intraepithelial neoplasia and carcinoma by fluorescence in situ hybridization | Q73919482 | ||
| P433 | issue | 9 | |
| P304 | page(s) | 1685-1699 | |
| P577 | publication date | 2018-06-29 | |
| P1433 | published in | Journal of Cancer Research and Clinical Oncology | Q2081599 |
| P1476 | title | Disruption of MEK/ERK/c-Myc signaling radiosensitizes prostate cancer cells in vitro and in vivo | |
| P478 | volume | 144 |
| Q64951143 | Biological Rationale for Targeting MEK/ERK Pathways in Anti-Cancer Therapy and to Potentiate Tumour Responses to Radiation. |
| Q98158987 | Dual effects of active ERK in cancer: A potential target for enhancing radiosensitivity |
| Q64266350 | HSP60 silencing promotes Warburg-like phenotypes and switches the mitochondrial function from ATP production to biosynthesis in ccRCC cells |
| Q92243738 | IGHG1 Regulates Prostate Cancer Growth via the MEK/ERK/c-Myc Pathway |
| Q92134426 | KIF15 Promotes Proliferation and Growth of Hepatocellular Carcinoma |
Search more.